Chengdu Xunyin Health Technology Advances Precision Prevention Medicine with Deep Genetic Analysis, Files for IPO

In the Era of Precision Medicine, Genetic Analysis Has Become the Most Fundamental and Critical Component of Health Management.

On one hand, routine physical examinations can only assess existing health conditions and fail to detect innate risks hidden within the genes. On the other hand, individuals vary in their genetic profiles, leading to differences in disease susceptibility, pathogenic mechanisms, and drug responses. Without genetic profiling, it is impossible to gain a deep understanding of individual differences at the cellular and molecular levels, which may compromise the effectiveness of health management and disease treatment.

Genetic testing can fill in the missing pieces of the “health information puzzle.” However, this technology is currently focused primarily on the traditional clinical domain of “treating existing diseases,” with severely insufficient application in scenarios related to “preventive medicine,” such as congenital risk assessment for chronic diseases and preventive management.

In this field, VCBeat has taken note of a unique health management company grounded in deep genetic analysis—Chengdu Xunyin Technology Co., Ltd. (brand and WeChat official account: “Xunyin Health”). Xunyin Health’s precision health management leverages genetic testing to comprehensively and deeply analyze individual genetic characteristics, precisely mapping differences in “constitution” to the genetic level. This approach can be widely applied across various stages of chronic disease prevention, diagnosis, and treatment. Xunyin Health not only provides consumers with key health insights at the genetic level but also empowers a broad range of health management institutions and practitioners, enabling them to deliver precise, personalized health management services to their end users.

Dr. Jiang Hao, founder of Xunyin Health, earned his degree from the University of California, Davis, and completed his postdoctoral research at the Scripps Research Institute. He currently serves as the Director of the Center for Gene Research and Translation at the Sichuan Tianfu Health Industry Research Institute. With over two decades of experience in molecular and cellular biology research, Dr. Jiang possesses extensive expertise in gene regulation and cell signaling. He holds multiple independent intellectual property rights in the fields of genetic health risk assessment, nutrigenomics, and pharmacogenomics.

The story of how Jiang Hao became involved with precision health management dates back to 2012.

In 2012, Jiang Hao joined a startup to engage in the early-stage development of consumer-grade nutrigenomics applications. During this period, he was first introduced to 23andMe, the pioneer in the field of direct-to-consumer genetic testing, and developed a strong interest in this sector. Reflecting on this experience, Jiang Hao admitted that he witnessed the awe that “genes”—which had previously existed only in laboratory test tubes and electrophoresis gels throughout his more than ten-year research career—could inspire in ordinary people. “Beyond publishing academic papers, this was the first time I realized that molecular genetics could be so closely intertwined with everyday life.” Consequently, Jiang Hao established his career in the field of genetic applications as his new, lifelong professional direction.

In 2016, Jiang Hao returned to China to work full-time. He observed that at the time, the application scenarios of consumer-grade genetic testing technology in the domestic market were primarily focused on ancestry analysis, disease risk assessment, and mental health management, while the field of nutrigenomics remained largely untapped. Jiang Hao aimed to introduce the new concepts of personalized health management he had studied and grasped over the previous few years to China, and he presciently recognized that traditional health management was due for an upgrade. In the same year, Xunyin Health was founded in Chengdu.

Jiang Hao explained that “Xun Yin” embodies the core philosophy the company’s brand seeks to convey: “We should not only understand our own genes but also ‘follow our genetic traits.’ Human health is determined by the combined influence of congenital and acquired risk factors. Although congenital risks cannot be altered, they can be identified and pinpointed through genetic testing. This enables highly targeted management of related acquired risk factors, along with appropriate specialized health screenings, thereby achieving precise and effective disease prevention.”

Genetic Traits: An Indispensable Part of the Health Information Puzzle

Guided by a profound understanding of gene significance and the shared philosophy that “prevention is better than cure,” Xunyin Health has attracted a cohort of like-minded partners. The company’s R&D team comprises specially appointed experts under Sichuan Province’s program for introducing high-caliber domestic and overseas talent, returnee Ph.D. holders from the United States, and professors from West China Hospital of Sichuan University and Army Medical University. All are frontline scientists with extensive experience in genetic research, possessing broad expertise in gene function across disciplines including genomics, bioinformatics, molecular and cell biology, and pharmacology.

The team is dedicated to elucidating the interplay between chronic diseases—such as cardiovascular and cerebrovascular disorders, diabetes, and cancer—and genetic factors. We provide customized chronic disease prevention and management plans based on individual genetic profiles. Through highly personalized dietary and nutritional guidance, lifestyle recommendations, and medication advice, we help prevent and mitigate chronic conditions, thereby enhancing quality of life.

In 2017, Xunyin Health independently developed a “polygenic risk” assessment algorithm, and over the course of three years, built from the ground up a technical system for personalized precision health management.By integrating cutting-edge research findings on chronic disease–gene associations through in-depth mining and translation, this system makes users’ most critical innate risks more explicit and prominent, establishing substantial technical advantages in both the precision and breadth of genetic health risk assessment.

Currently, consumer-grade genetic products are not uncommon in the market. However, Jiang Hao points out that due to cost-control measures or insufficient R&D investment, some products suffer from a severe lack of tested and evaluated loci. The generalized, broad, and even “false-positive” or “false-negative” conclusions they provide lack reference value. Furthermore, these products often list numerous risk factors, making it difficult for users to identify which ones warrant attention, thereby failing to realize the significant value that genetic analysis should offer in health management.

A comprehensive and in-depth understanding of the characteristics of known genetic loci associated with specific chronic diseases is a prerequisite for assessing individual genetic health risks and serves as the basis for health management. “It is precisely with this consideration in mind thatXunyin Health conducts an in-depth mining of scientific literature on the association between chronic diseases and genes, comprehensively screening a series of health risk genes and loci established through extensive and rigorous scientific research, ensuring that every genetic analysis conclusion is supported by reliable scientific evidence.”, Jiang Hao explained, “All products launched by Xunyin Health cover relevant risk loci as comprehensively as possible. We will not rush to capture market share with products that we believe cannot yield reliable assessment conclusions. Meanwhile, through case accumulation and continuous optimization, the company will constantly refine its risk assessment algorithms and customized guidance plans.”

Currently,Xunyin Health covers congenital risk assessment for over 200 chronic diseases across 12 major categories, as well as comprehensive screening for more than 6,000 genetic disorders.. The company focuses on complex polygenic chronic diseases, specializing in the field of precision preventive medicine centered on “treating before disease onset.” According to Jiang Hao, the breadth and depth achieved by Xunyin Health’s chronic disease risk assessment project are relatively rare in the current domestic market.

Inherited Risk Assessment for 12 Major Categories of Complex Polygenic Chronic Diseases

Xunyin Health’s health management products go beyond mere testing.For the company, genetic testing is merely a technical tool; Xunyin Health is more committed to providing users with customized solutions for chronic disease prevention and medication based on individual genetic characteristics, rather than stopping at generalized assessments of high or low risk.“Currently, consumer-grade genetic testing services on the market often lack report interpretation and follow-up risk management plans. In contrast, Xunyin Health not only identifies issues but also provides solutions,” Jiang Hao explained to VCBeat.

Regarding its target audience, Jiang Hao told VCBeat that its precision management solutions are primarily geared toward high-potential-demand groups for health management, such as subhealthy individuals outside the clinical setting and currently healthy individuals with immediate family members suffering from critical illnesses.

“Xunyin Health can analyze genetic traits for individuals in a sub-health state or those with abnormal health checkup indicators, helping to customize personalized dietary nutrition and lifestyle improvement plans to delay or even prevent the onset of chronic diseases. For currently healthy individuals whose first-degree relatives suffer from chronic diseases, Xunyin Health will help assess their disease risk and develop personalized prevention strategies based on the characteristics of relevant risk genes, thereby achieving the goal of ‘superior physicians treating disease before it arises,’” said Jiang Hao.

For patients with chronic diseases, traditional medical practice often prescribes the same medication for identical conditions. However, genotypes related to drug metabolism vary among individuals, leading to interpatient variability in actual drug efficacy. This can result in extremely high rates of medication inefficacy, causing waste of medical resources and suboptimal therapeutic outcomes.It is understood that, based on individual genetic profiles, Xunyin Health can develop more effective and safer personalized medication regimens and dosages for over 850 drugs, including oncology chemotherapeutic agents and medications for chronic diseases.

“Except for acquired somatic mutations and epigenetic modifications, the human genetic composition remains unchanged. However, science is advancing rapidly; unknown risks that are currently undetected may become fully apparent in the near future,” explained Jiang Hao. Based on this, Xunyin Health continuously optimizes its existing offerings and adds new risk assessment items by tracking scientific frontiers, mining literature, and leveraging proprietary big data analytics, thereby providing users with updated analysis reports on an irregular basis.

All analyses and guidance provided by Xunyin Health are conducted by technical professionals in relevant fields to ensure a high level of expertise. Specifically, Xunyin Health requires registered dietitians with clinical nutrition counseling experience, health managers with health management guidance experience, or even licensed clinicians to conduct approximately 30-minute one-on-one consultations. Based on a thorough understanding of the user’s height, weight, age, gender, and daily meal patterns, and integrating comprehensive health information—including genetic traits, personal medical history, family medical history, physical examination indicators, dietary nutrition, lifestyle habits, and medication usage—these professionals customize personalized recommendations for dietary nutrition, targeted health screenings, lifestyle and exercise, and medication management. As health status is dynamic, Xunyin Health’s precision health management system continuously self-improves and iterates while introducing more cutting-edge products and technologies, providing holistic health care for entire families across the entire life cycle.

 Xunyin Health’s Precision Health Management System and Service Offerings

Regarding the current state of genetic testing technology, Jiang Hao stated that its applications have yet to significantly benefit the fields of chronic disease prevention and health management, particularly in the areas of complex polygenic chronic diseases and nutrigenomics. “As a novel interdisciplinary field and specialized niche, nutrigenomics is an important tool for personalized health management and preventive medicine. Under the prevailing paradigm of ‘prevention over treatment,’ it is poised to deliver unprecedented value in enhancing quality of life.”

In the future, the company also plans to build a platform for health management practitioners to empower health managers, nutritionists, and medical personnel, enhance the level of medical services, and drive the development of the broader health industry.